Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21903316 | 0.83 | IDO1 (0.44) | CTSSCTSLCTSBAKT1KMT2A | |
| SCHEMBL4702416 | 0.83 | AKT1 (0.46) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL5194439 | 0.81 | KMT2A (0.49) | KMT2AMEN1NPC1RAB9ARIPK1 | |
| SCHEMBL15261600 | 0.81 | HTR2C (0.43) | CTSSCTSKAKT1KMT2AMEN1 | |
| SCHEMBL4702705 | 0.79 | KMT2A (0.40) | CTSSCTSLCTSBAKT1KMT2A | |
| SCHEMBL4702707 | 0.78 | CTSL (0.39) | CTSSCTSLCTSBAKT1KMT2A | |
| SCHEMBL1329466 | 0.78 | RIPK1 (0.60) | CTSSCTSKKMT2AMEN1NPC1 | |
| SCHEMBL11358459 | 0.78 | RIPK1 (0.54) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL12232503 | 0.76 | CTSL (0.41) | CTSSCTSLCTSBAKT1KMT2A | |
| SCHEMBL29793814 | 0.76 | NQO2 (0.56) | CTSSCTSKKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339133-B2 | Method for producing triazolidinedione compound | TOKUYAMA CORPORATION (JP) | 2022-05-24 | — | — | US | disclosed |
| US-20210253541-A1 | METHOD FOR PRODUCING TRIAZOLIDINEDIONE COMPOUND | TOKUYAMA CORPORATION (JP) | 2021-08-19 | — | — | US | disclosed |
| EP-3808735-A1 | METHOD FOR PRODUCING TRIAZOLIDINEDIONE COMPOUND | Tokuyama Corporation (JP) | 2021-04-21 | — | — | EP | disclosed |
| CN-112236418-A | Process for producing triazolidinedione compound | 株式会社德山 | 2021-01-15 | — | — | CN | disclosed |
| US-8987263-B2 | Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-03-24 | — | — | US | disclosed |
| EP-1532103-A4 | USE OF COMPOUNDS HAVING AN AMINE NUCLEUS IN MANUFACTURE OF A MEDICAMENT USEFUL FOR TREATING FACTOR VIIA-ASSOCIATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20060173057-A1 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | HERPIN TIMOTHY | 2006-08-03 | — | — | US | disclosed |
| US-20060173053-A1 | Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2006-08-03 | — | — | US | disclosed |
| US-7041692-B2 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1551495-A2 | BASIC ESTERS OF FATTY ALCOHOLS AND THEIR USE AS ANTI-INFLAMMATORY OR IMMUNOMODULATORY AGENTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-07-13 | — | — | EP | disclosed |
| EP-1532103-A2 | USE OF COMPOUNDS HAVING AN AMINE NUCLEUS IN MANUFACTURE OF A MEDICAMENT USEFUL FOR TREATING FACTOR VIIA-ASSOCIATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004032824-A2 | BASIC ESTERS OF FATTY ALCOHOLS AND THEIR USE AS ANTI-INFLAMMATORY OR IMMUNOMODULATORY AGENTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-04-22 | — | — | WO | disclosed |
| US-20040029940-A1 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-12 | — | — | US | disclosed |
| WO-2004000788-A1 | UREIDO-SUBSTITUTED ANILINE COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000214-A2 | USE OF COMPOUNDS HAVING AN AMINE NUCLEUS IN MANUFACTURE OF A MEDICAMENT USEFUL FOR TREATING FACTOR VIIA-ASSOCIATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
| US-6596747-B2 | For therapy of diseases associdated with Factor VIIa and or inosine monophosphate dehydrogenase (IMPDH) | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-20020143176-A1 | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173057-A1 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | F7, F8, F13B | CTSS 957/4885CTSK 1140/4885CTSL 1426/4885 |
| US-20210253541-A1 | METHOD FOR PRODUCING TRIAZOLIDINEDIONE COMPOUND | WEE1, PEAK1, ITK | CTSS 2748/4885CTSK 508/4885CTSL 2564/4885 |
| US-20020143176-A1 | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same | IMPDH1, IMPDH2, IMPA1 | CTSS 924/4885CTSK 1476/4885CTSL 850/4885 |
| US-20060173053-A1 | Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents | ALOX12, ALOX15, ALOX15B | CTSS 3410/4885CTSK 4440/4885CTSL 3283/4885 |
| US-20040029940-A1 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | F7, F8, F13B | CTSS 1053/4885CTSK 1206/4885CTSL 1520/4885 |
| US-11339133-B2 | Method for producing triazolidinedione compound | WEE1, PEAK1, ITK | CTSS 2748/4885CTSK 508/4885CTSL 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.